Dynavax Technologies Corporation
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $13.43
- Today's High:
- $13.675
- Open Price:
- $13.43
- 52W Low:
- $9.42
- 52W High:
- $17.48
- Prev. Close:
- $13.48
- Volume:
- 913299
Company Statistics
- Market Cap.:
- $1.48 billion
- Book Value:
- 4.388
- Revenue TTM:
- $655.62 million
- Operating Margin TTM:
- 40.19%
- Gross Profit TTM:
- $448.22 million
- Profit Margin:
- 35.99%
- Return on Assets TTM:
- 16.64%
- Return on Equity TTM:
- 55.44%
Company Profile
Dynavax Technologies Corporation had its IPO on 2004-02-19 under the ticker symbol DVAX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Dynavax Technologies Corporation has a staff strength of 351 employees.
Stock update
Shares of Dynavax Technologies Corporation opened at $13.43 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.43 - $13.68, and closed at $13.51.
This is a +0.22% increase from the previous day's closing price.
A total volume of 913,299 shares were traded at the close of the day’s session.
In the last one week, shares of Dynavax Technologies Corporation have slipped by -7.08%.
Dynavax Technologies Corporation's Key Ratios
Dynavax Technologies Corporation has a market cap of $1.48 billion, indicating a price to book ratio of 2.8674 and a price to sales ratio of 1.9432.
In the last 12-months Dynavax Technologies Corporation’s revenue was $655.62 million with a gross profit of $448.22 million and an EBITDA of $267.31 million. The EBITDA ratio measures Dynavax Technologies Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Dynavax Technologies Corporation’s operating margin was 40.19% while its return on assets stood at 16.64% with a return of equity of 55.44%.
In Q1, Dynavax Technologies Corporation’s quarterly earnings growth was a negative -30.9% while revenue growth was a negative 58.8%.
Dynavax Technologies Corporation’s PE and PEG Ratio
- Forward PE
- 6.3573
- Trailing PE
- 7.2642
- PEG
- 0
Its diluted EPS in the last 12-months stands at $1.59 per share while it has a forward price to earnings multiple of 6.3573 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dynavax Technologies Corporation’s profitability.
Dynavax Technologies Corporation stock is trading at a EV to sales ratio of 1.5092 and a EV to EBITDA ratio of 3.2494. Its price to sales ratio in the trailing 12-months stood at 1.9432.
Dynavax Technologies Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $969.92 million
- Total Liabilities
- $91.52 million
- Operating Cash Flow
- $-52334000.00
- Capital Expenditure
- $1.36 million
- Dividend Payout Ratio
- 0%
Dynavax Technologies Corporation ended 2024 with $969.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $969.92 million while shareholder equity stood at $563.73 million.
Dynavax Technologies Corporation ended 2024 with $0 in deferred long-term liabilities, $91.52 million in other current liabilities, 128000.00 in common stock, $-948527000.00 in retained earnings and $2.04 million in goodwill. Its cash balance stood at $174.35 million and cash and short-term investments were $651.96 million. The company’s total short-term debt was $0 while long-term debt stood at $221.86 million.
Dynavax Technologies Corporation’s total current assets stands at $830.14 million while long-term investments were $0 and short-term investments were $477.61 million. Its net receivables were $101.74 million compared to accounts payable of $7.30 million and inventory worth $57.69 million.
In 2024, Dynavax Technologies Corporation's operating cash flow was $-52334000.00 while its capital expenditure stood at $1.36 million.
Comparatively, Dynavax Technologies Corporation paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $13.51
- 52-Week High
- $17.48
- 52-Week Low
- $9.42
- Analyst Target Price
- $22.8
Dynavax Technologies Corporation stock is currently trading at $13.51 per share. It touched a 52-week high of $17.48 and a 52-week low of $17.48. Analysts tracking the stock have a 12-month average target price of $22.8.
Its 50-day moving average was $14.08 and 200-day moving average was $11.86 The short ratio stood at 15.67 indicating a short percent outstanding of 0%.
Around 24% of the company’s stock are held by insiders while 9294.1% are held by institutions.
Frequently Asked Questions About Dynavax Technologies Corporation
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.